{
    "id": "52831748",
    "text": "Prexasertib (LY2606368) is a small molecule checkpoint kinase inhibitor, mainly active against CHEK1, with minor activity against CHEK2. This causes induction of DNA double-strand breaks resulting in apoptosis. It is in development by Eli Lilly. A phase II clinical trial for the treatment of small cell lung cancer is expected to be complete in December 2017. == References == Category:Experimental cancer drugs Category:Protein kinase inhibitors Category:Pyrazoles Category:Pyrimidines Category:Nitriles ",
    "title": "Prexasertib"
}